Trials / Recruiting
RecruitingNCT06176508
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic Arthritis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10374 | Administered orally QD for 16 weeks |
| DRUG | HS-10374-matched placebo tablets | Administered orally QD for 16 weeks |
| DRUG | Tofacitinib 5Mg Tab,Oral | Administered orally BID for 16 weeks |
Timeline
- Start date
- 2024-02-26
- Primary completion
- 2026-04-28
- Completion
- 2026-08-28
- First posted
- 2023-12-19
- Last updated
- 2024-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06176508. Inclusion in this directory is not an endorsement.